Cremophor News and Research

RSS
Cremophor is an emulsifying agent for the pharmaceuticals, cosmetics and feedstuffs industries; used in aqueous preparations of hydrophobic substances, e.g. fat-soluble vitamins and essential oils.
Scientists use novel technology for opening blood-brain barrier with implantable ultrasound

Scientists use novel technology for opening blood-brain barrier with implantable ultrasound

Oasmia announces topline results from head-to-head comparison study of Paclical and Abraxane

Oasmia announces topline results from head-to-head comparison study of Paclical and Abraxane

Sorrento, IGDRASOL to present updates on IG-001 and IG-004 at joint meeting of CLINAM and ETPN

Sorrento, IGDRASOL to present updates on IG-001 and IG-004 at joint meeting of CLINAM and ETPN

Sorrento Therapeutics, IGDRASOL announce publication of clinical data for Cynviloq and gemcitabine

Sorrento Therapeutics, IGDRASOL announce publication of clinical data for Cynviloq and gemcitabine

Sorrento Therapeutics, IGDRASOL to present updates on Cynviloq at Nanomedicine 2013 meeting

Sorrento Therapeutics, IGDRASOL to present updates on Cynviloq at Nanomedicine 2013 meeting

IGDRASOL to present updates on Cynviloq at AACR annual meeting

IGDRASOL to present updates on Cynviloq at AACR annual meeting

NeuroVive announce results from CicloMulsion Phase I trial on cardiac reperfusion injury

NeuroVive announce results from CicloMulsion Phase I trial on cardiac reperfusion injury

Researchers test nanoscale carbon clusters for cancer chemotherapy

Researchers test nanoscale carbon clusters for cancer chemotherapy

Treatment commences in NeuroVive-HCL's 1,000 patient European cardioprotection trial

Treatment commences in NeuroVive-HCL's 1,000 patient European cardioprotection trial

NeuroVive, HCL initiate CicloMulsion Phase III trial in myocardial infarction

NeuroVive, HCL initiate CicloMulsion Phase III trial in myocardial infarction

Findings from Abraxis BioScience's phase 3 ABRAXANE trial in patients with NSCLC presented at ASCO

Findings from Abraxis BioScience's phase 3 ABRAXANE trial in patients with NSCLC presented at ASCO

Cremophor-based paclitaxel ‘chemo’ drug triggers fatal allergic reactions

Cremophor-based paclitaxel ‘chemo’ drug triggers fatal allergic reactions

FDA approves approved Ixempra (ixabepilone) for advanced breast cancer

FDA approves approved Ixempra (ixabepilone) for advanced breast cancer

New York Times examines efforts to obtain FDA approval for Abraxane to treat earlier-stage cancer

New York Times examines efforts to obtain FDA approval for Abraxane to treat earlier-stage cancer

Abraxane, first in a new class of albumin-bound nanotechnology for the treatment of metastatic breast cancer

Abraxane, first in a new class of albumin-bound nanotechnology for the treatment of metastatic breast cancer

Promising new cancer drug, Nanotax

Promising new cancer drug, Nanotax